Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Diabetes

    Houston, TX

    Search
    Diabetes
    Houston, TX
    Show Map
    Map View
    Houston, TX
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      123 Diabetes Trials near Houston, TX

      Power is an online platform that helps thousands of Diabetes patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Petrelintide for Obesity and Type 2 Diabetes

      Houston, Texas
      The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Severe Hypoglycemia, Obesity Surgery, Others
      Must Be Taking:Metformin, SGLT2 Inhibitors

      216 Participants Needed

      Macupatide + Eloralintide for Obesity

      Houston, Texas
      The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Cardiovascular Conditions, Malignancy, Others
      Must Be Taking:Metformin, SGLT2 Inhibitors

      200 Participants Needed

      NEW Diabetes and Pain Medication Study

      Houston, Texas
      This trial tests a daily pill called NRD135S.E1 for people with painful nerve damage from diabetes. The study will see if taking this pill for a few months can safely reduce their pain. Researchers aim to understand how well the drug works and if it is safe to use.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Substance Abuse, Renal Impairment, Heart Disease, Others
      Must Not Be Taking:Prohibited Medications

      122 Participants Needed

      Del-desiran for Myotonic Dystrophy

      Houston, Texas
      A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3
      Age:16+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Non-compliance, New Conditions, Others

      217 Participants Needed

      Del-desiran for Myotonic Dystrophy

      Houston, Texas
      A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:16 - 65

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Uncontrolled Diabetes, Heart Failure, Others
      Must Not Be Taking:Anti-myotonic Medications

      159 Participants Needed

      Carnitine Supplementation for Arterial Stiffness

      Houston, Texas
      Hardening of the blood vessels, called arterial stiffness, is a risk factor for future heart disease and its causes are unclear. The proposed study will 1) randomly assign adolescents at high risk of stiffening blood vessels to take a protein supplement called carnitine and study its effects on arterial stiffening and 2) study carnitine related genes for their effect on arterial stiffening. The study will definitively establish a role for carnitine action as a cause of stiffening blood vessels and signal a way to treat or prevent stiffening.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:11 - 21

      Key Eligibility Criteria

      Disqualifiers:Seizure Disorder, Renal Failure, Diabetes, Others

      90 Participants Needed

      Lifestyle Physical Activity for Metabolic Diseases

      Houston, Texas
      When muscles are not contracting, the local energy demand by muscle and use of specific fuels used to produce energy by oxidative metabolism are minimal. The time people spend sitting inactive (sedentary time) typically comprises more than half of the day. This sedentary behavior is associated with elevated risk of diabetes, cardiovascular diseases, some cancers, and multiple conditions leading to poor aging. From a progressive series of experiments, the driving goal is to develop a physiological method for sustaining contractile activity via oxidative metabolism over more time than is possible by traditional exercise (hours, not minutes per day). Developing a physiological method suitable of prolonged muscular activity for ordinary people (who are often unfit) requires gaining fundamental insights about muscle biology and biomechanics. This also entails a careful appreciation of the ability to isolate specific muscles in the leg during controlled movements, such as the soleus muscle during isolated plantarflexion. This includes quantifying specific biological processes that are directly responsive to elevated skeletal muscle recruitment. The investigators will focus on movement that is safe and practical for ordinary people to do given their high amount of daily sitting time. This includes developing methods to optimally raise muscle contractile activity, in a way that is not limited by fatigue, and is feasible throughout as many minutes of the day as possible safely. This also requires development of methodologies to quantify specific muscular activity, rather than generalized body movement. There is a need to learn how much people can increase muscle metabolism by physical activity that is perceived to them as being light effort. It is important to learn if this impacts systemic metabolic processes under experimental conditions over a short term time span in order to avoid confounding influences of changes in body weight or other factors.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Eating Disorder, Others
      Must Not Be Taking:Anticoagulants

      60 Participants Needed

      Long-Term Use of Relacorilant for Cushing Syndrome

      Houston, Texas
      This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Hypothyroidism, Hyperthyroidism, Hypertension, Renal Failure
      Must Be Taking:Relacorilant

      125 Participants Needed

      AU-007 for Advanced Cancer

      Houston, Texas
      This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w). Once the recommended phase 2 dose (RP2D) of AU-007 plus aldesleukin was determined, (AU-007 Q2w plus a single loading dose of aldesleukin), AU-007 plus aldesleukin is also being administered with avelumab or nivolumab.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disease, Major Surgery, Others
      Must Not Be Taking:Immune-suppressive Drugs

      159 Participants Needed

      LY3841136 + Tirzepatide for Obesity with Type 2 Diabetes

      Houston, Texas
      The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Severe Hypoglycemia, Cardiovascular Conditions, Renal Impairment, Others
      Must Be Taking:Metformin, SGLT2 Inhibitors

      350 Participants Needed

      Tremelimumab for Mesothelioma

      Houston, Texas
      This is a Phase 2b, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo. Approximately 564 subjects will be enrolled at study centers in multiple countries. The study consists of a screening period, a treatment period, a 90-day follow-up period for safety, and a long-term survival follow-up period.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disease, CNS Metastasis, Others
      Must Not Be Taking:Corticosteroids, Immunosuppressants

      571 Participants Needed

      Symphony™ Treatment for Diabetic Foot Ulcers

      Houston, Texas
      This trial will test Symphony™, a special wound treatment, on patients with chronic diabetic foot ulcers that don't heal with regular care. The treatment helps wounds heal faster by providing extra support.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:HIV, Hepatitis C, Poor Metabolic Control, Others
      Must Not Be Taking:Immune-suppressants, Chemotherapy, Topical Steroids, Others

      120 Participants Needed

      Investigational Procedure for Type 2 Diabetes and Gum Disease

      Houston, Texas
      The purpose of this study is to learn about the interactions of markers of type 2 diabetes (T2DM) and periodontitis (PD). Study VPE00001 is a multi-center cross-sectional study. Participants will be categorized based on point-of-care hemoglobin A1c (HbA1c) and periodontal disease (PD) staging into 9 subgroups. The key objectives of the study are: * To evaluate immune signatures in well-characterized populations with or without PD and/or T2DM * To evaluate baseline clinical biomarkers of T2DM and PD in well-characterized populations * To evaluate the influence of clinical, immunological, and microbiological biomarkers on the bidirectional relationship between T2DM and PD
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:30 - 70

      Key Eligibility Criteria

      Disqualifiers:Bleeding Disorder, HIV, Hepatitis, Others
      Must Not Be Taking:Anticoagulants, Antibiotics, Immunosuppressants, Others

      300 Participants Needed

      Botensilimab + Balstilimab for Colorectal Cancer

      Houston, Texas
      This trial tests botensilimab alone or with balstilimab in adults with advanced colorectal cancer who didn't respond to previous chemotherapy. The new drugs aim to enhance the immune system's ability to fight cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Active Brain Metastases, Cardiovascular Disease, Autoimmune Disease, Others
      Must Not Be Taking:Immune Checkpoint Inhibitors

      234 Participants Needed

      KL1333 for Mitochondrial Disease

      Houston, Texas
      This trial is testing KL1333, a new medicine, to see if it can help people with mitochondrial disease feel less tired and improve their physical abilities. The study targets people with primary mitochondrial disease because they often suffer from severe fatigue. KL1333 works by boosting energy production in cells.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Neurodegenerative Phenotypes, Cardiovascular Disease, Gastrointestinal Issues, Others
      Must Not Be Taking:Idebenone

      180 Participants Needed

      CSL300 for Kidney Failure

      Houston, Texas
      This trial is testing CSL300, a new treatment, to see if it helps people with heart disease or diabetes who are on dialysis. The study aims to find the right dose and check if it improves heart health by reducing inflammation.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Abnormal LFTs, Life-threatening Disease, Others
      Must Not Be Taking:Immunosuppressants

      2310 Participants Needed

      Bimagrumab + Tirzepatide for Obesity with Type 2 Diabetes

      Houston, Texas
      The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 13 months.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Hypertension, Cardiovascular, Renal, Others
      Must Not Be Taking:Weight Loss Drugs

      180 Participants Needed

      Retatrutide for Obesity

      Houston, Texas
      The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:45+

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Recent Heart Attack, Others

      10000 Participants Needed

      GSK3858279 for Diabetic Neuropathy

      Houston, Texas
      This is a multicenter randomized, double-blind, placebo-controlled phase 2 study to evaluate efficacy, safety, tolerability, pharmacokinetics, and target engagement of GSK3858279 in adult participants with chronic Diabetic Peripheral Neuropathic Pain (DPNP). The primary objective of the study is to assess the efficacy of GSK3858279 in participants with DPNP who have been unable to sufficiently manage their pain.

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      145 Participants Needed

      Bionic Pancreas for Cystic Fibrosis

      Houston, Texas
      This multi-center randomized controlled trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP) versus a control group using their usual care insulin delivery method and continuous glucose monitoring (CGM) during a 13-week study period in individuals ≥14 years old with cystic fibrosis-related diabetes (CFRD). After 13 weeks, participants will continue in a 13-week Extension Phase in which the BP group will continue to use the BP system and the Usual Care group will initiate use of the BP system.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:14+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Transplant, Severe Liver Disease, Others
      Must Be Taking:Insulin

      150 Participants Needed

      Why Other Patients Applied

      "Years ago, Metformin didn't help. I'm currently on Rybelsus & Farxiga. Not doing me much good. My insurance won't cover any of the injectables. Excited to try something new."

      QL
      Diabetes PatientAge: 71

      "Looking for better ways to manage my diabetes, high blood pressure and overall health. Hoping to improve my health all together in order to have a better life & to enjoy my children & grandchildren."

      OK
      Diabetes PatientAge: 66

      "I've been in pain for years. It's been crippling and has massively impacted my life. I want to be free. Diabetes changed everything at 15. Diabetic Type 1 for 20 years. SEVERE Peripheral Neuropathy onset 7-8 years in. Have been living with it since. Have tried every drug, everything. Gaba, lyrica, all opioids, electrical current therapy, massages, acupuncture, cupping, everything. Currently taking low dose of duloxetine, have an insulin pump but its not good enough. Want to try a cutting-edge med."

      YN
      Diabetes PatientAge: 35

      "I have struggled with weight management after having bariatric surgery over 5 years ago and have regained what I have lost. I'm looking to participate in a trial that can help me get my life back under control."

      IJ
      Diabetes PatientAge: 25

      "I have had type 2 diabetes for some time now and would love to be part of a study... should the study drug work out as a successful treatment, then I would be glad to be one of the first patients in line!"

      MB
      Diabetes PatientAge: 67
      Match to a Diabetes Trial

      Healthy Lifestyle Program for Fatty Liver Disease

      Houston, Texas
      The purpose of this study is to understand if a behavioral lifestyle intervention called the Healthy Liver/Hígado Sano program can help Hispanic/Latino patients with metabolic dysfunction associated steatotic liver disease (MASLD), also known as non-alcoholic fatty liver disease (NAFLD), lose weight and improve their liver health
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:No Phone Number

      64 Participants Needed

      Combination Antibody Therapy for Large B-Cell Lymphoma

      Houston, Texas
      This phase II trial studies the effect of brentuximab vedotin and nivolumab alone and in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone in treating patients with untreated, stage I-IV primary mediastinal large B-cell lymphoma. Brentuximab vedotin is a monoclonal antibody, called brentuximab, linked to a toxic agent, called vedotin. Brentuximab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD30 receptors, and delivers vedotin to kill them. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Rituximab is a type of antibody therapy, which targets and attaches to the CD20 protein found on the surface of blood cells with cancer and some healthy blood cells. Chemotherapy drugs, such as cyclophosphamide, and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, or by stopping them from dividing. Prednisone is a steroid, a hormone (chemical messengers) with multiple roles, notably in the immune system and inflammation reduction. Steroids are poisonous to lymphocytes (white blood cells from which lymphomas develop). Giving brentuximab vedotin and nivolumab in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone may help to control the disease and be a less harmful regimen than standard chemotherapy in patients with primary mediastinal large B-cell lymphoma.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Hypertension, Diabetes, HIV, Others
      Must Not Be Taking:Anthracyclines, HAART

      31 Participants Needed

      RO7795081 for Type 2 Diabetes

      Bellaire, Texas
      This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of RO7795081 for glycemic control in adult participants with Type 2 diabetes mellitus (T2D).

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Retinopathy, Nephropathy, Neuropathy, Others
      Must Be Taking:Metformin, SGLT-2 Inhibitors

      240 Participants Needed

      Insulin Management Strategies for Diabetes during Pregnancy

      Houston, Texas
      There is a fundamental gap in understanding the maternal and neonatal effects of antenatal corticosteroid (ACS) administration in women with threatened preterm birth (PTB) who have diabetes. Since the initial discovery of ACS for neonatal benefit in 1972, more than 40 randomized controlled trials have been performed evaluating its efficacy. However, none of these trials have included women with T2DM, and there is limited data among women with gestational diabetes. While ACS have been shown to reduce neonatal morbidity associated with PTB in non-diabetic women, the side effects of ACS (maternal hyperglycemia and fetal hyperinsulinemia) may mitigate the neonatal benefit of ACS in women with diabetes. Before neonatal benefit of ACS can be evaluated in this population, the first step is to optimize maternal glycemic control after ACS. Previous studies evaluating maternal hyperglycemia after ACS have been limited by small sample size, retrospective study design, or insufficient glucose data. Use of continuous glucose monitoring (CGM) in a randomized clinical trial provides a unique opportunity to overcome these challenges. Our long-term goal is to improve maternal and child health among women with diabetes as an independently funded clinical researcher. The research objectives of this proposal are to test the efficacy of three treatment strategies at achieving maternal glycemic control after ACS and evaluate the association between maternal glycemic control and neonatal outcomes. Our central hypothesis is that treatment with a continuous insulin infusion will improve maternal glycemic control, which is key to improving neonatal outcomes, but at the cost of less patient satisfaction and more health resource utilization. This hypothesis will be tested by pursuing the following specific aims: 1) Test the efficacy of three treatment strategies (addition of sliding scale insulin, up-titration of home insulin, and continuous insulin infusion) at achieving maternal glycemic control after ACS and 2) Quantify the association between maternal glycemic control after ACS and neonatal morbidity. Completion of these aims will determine the optimal strategy to achieve maternal glycemic control after ACS and inform a larger, multicenter trial to improve neonatal outcomes among women with diabetes and threatened PTB.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:0 - 50

      Key Eligibility Criteria

      Disqualifiers:Major Fetal Anomaly, Triplet, Others
      Must Be Taking:Insulin, Metformin

      120 Participants Needed

      Weekly vs Daily Insulin for Type 2 Diabetes

      Houston, Texas
      This study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes. Participants will either get insulin icodec or insulin glargine. Which treatment participants get is decided by chance. Insulin icodec is the new medicine being tested, while insulin glargine is already approved and can be prescribed by doctors. Participants will get one injection of insulin icodec once a week, or one injection of insulin glargine once a day, depending on the treatment group participants are assigned into. Participants will use a pen with a small needle to inject the medicine under participants skin into participants thigh, upper arm or stomach.The study will last for about 9 months, but participants will only be taking the study medicine for 6 months.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Diabetic Ketoacidosis, Myocardial Infarction, Others
      Must Be Taking:Basal Insulin

      404 Participants Needed

      CagriSema for Type 2 Diabetes

      Houston, Texas
      This study will look at how much CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participant will get either CagriSema or "dummy" medicine and which treatment they get is decided by chance. Participant will take the study medicine together with their current diabetes medicine (once-daily insulin with or without metformin). For each participant, the study will last for about one year.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Renal Impairment, Others
      Must Be Taking:Basal Insulin, Metformin

      270 Participants Needed

      AEYE-DS Software for Diabetic Retinopathy

      Houston, Texas
      The goal of this clinical trial is to learn about the performance of the AEYE-DS Software Device to automatically detect more than mild Diabetic Retinopathy (mtmDR) in adult participants diagnosed with Diabetic Mellitus (DM) using fundoscopic images of the eyes. The main question it aims to answer is if the software is effective in diagnosing more than mild Diabetic Retinopathy (mtmDR) in patients with known diabetes using digital funduscopic images, acquired from each of the participating fundoscopy devices and based on one macula centered image per eye. Participants: * will have an eye exam in which photographic images of each eye will be taken by a novice operator, using four different FDA approved/registered fundoscopy cameras. These images will be sent to and analyzed by the AEYE-DS software device. * will have additional eye imaging taken using a different FDA approved desktop camera system by a professional ophthalmic photographer. These images will be sent to an independent reading center for analysis. * will have dilation drops put in their eyes (either during or after the imaging with the fundoscopy cameras), wait about 30 minutes for the pupils to dilate and continue the eye imaging exams. The outcome results with the AEYE-DS Software will be compared to the analysis of the eye images processed by the reading center to see if the investigational software device was accurate in its diagnosis.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Age:22+

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      601 Participants Needed

      Retatrutide for Chronic Kidney Disease and Obesity

      Houston, Texas
      This trial is testing a medication called retatrutide to see if it can help improve kidney function. The study focuses on people who are overweight or obese and have chronic kidney disease, with or without Type 2 Diabetes. The goal is to find out if this medication can make their kidneys work better.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Obesity Surgery, Type 1 Diabetes, Hepatitis, Others
      Must Be Taking:Oral Antihyperglycemics, Basal Insulin

      146 Participants Needed

      AT-001 for Diabetic Cardiomyopathy

      Houston, Texas
      This trial is testing a new drug called AT-001 to see if it can help adults with a heart condition related to diabetes. The goal is to improve their heart function or prevent it from getting worse, especially for those at high risk of severe heart failure.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:40+

      Key Eligibility Criteria

      Disqualifiers:Heart Failure, Coronary Disease, Arrhythmia, Others

      675 Participants Needed

      BMF-219 for Type 1 Diabetes

      Houston, Texas
      This trial tests BMF-219, an oral medication that blocks a protein called menin, in people with Type 1 Diabetes. The goal is to see if it can help their insulin-producing cells work better and improve how their bodies handle sugar and fats.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:MODY, T2D, Cardiovascular Disease, Others
      Must Be Taking:Insulin

      37 Participants Needed

      12345

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Diabetes clinical trials in Houston, TX pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Diabetes clinical trials in Houston, TX work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Diabetes trials in Houston, TX 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Houston, TX for Diabetes is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Houston, TX several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Diabetes medical study in Houston, TX?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Diabetes clinical trials in Houston, TX?

      Most recently, we added Adalimumab + Verapamil for Type 1 Diabetes, Smart Insoles + Diabetes Education for Diabetes and Infliximab for Diabetes to the Power online platform.

      What is the best treatment for diabetes?

      There isn’t one “best” therapy—think of diabetes care as two layers. First, everyone benefits from diabetes education, a balanced diet, regular activity, and routine monitoring. Second, medicines are chosen by diabetes type and other health issues: type 1 always needs insulin (preferably with a continuous glucose monitor or hybrid pump), while type 2 usually starts with metformin plus lifestyle changes and, if more help is needed, adds a GLP-1 or SGLT2 drug (especially when heart, kidney, or weight problems exist) before considering insulin. Work with your healthcare team to revisit these steps every few months so treatment keeps pace with your goals and any new health changes.

      How much weight do you need to lose to reverse type 2 diabetes?

      Most studies find that you need to shed about 10–15 % of your starting weight—roughly 15 kg (33 lb) for an average-sized adult—to give yourself the best shot at putting type-2 diabetes into remission (normal sugars without diabetes pills). The closer you are to diagnosis and the more weight you keep off—especially if you can pass the 15 kg mark—the higher the odds (up to 80 % in some trials), while smaller losses still improve blood sugar but rarely achieve full remission. Work with your healthcare team to choose a safe approach (intensive diet program, GLP-1 medications, or bariatric surgery) and to monitor that blood-sugar targets stay on track once the weight comes off.

      Can diabetics still get Ozempic?

      Yes—if you have type-2 diabetes and meet NICE criteria (poor glucose control despite other drugs, or need for weight loss/heart-protection), your GP or diabetes nurse can still prescribe Ozempic; it is not used for type-1 diabetes, pregnancy, or in children. The practical hurdle is the current UK supply shortage, so existing users should order repeats early and stay in touch with their pharmacist, while new patients may need to start a similar medicine (e.g., dulaglutide) until stock returns.

      When will oral insulin be available?

      No insulin pill has been approved yet. The most advanced candidates (such as insulin tregopil and ORMD-0801) are still redesigning or preparing large Phase 3 studies, and newer “chocolate-capsule” nano-formulations have not even begun human trials until at least 2025. If upcoming studies succeed, regulatory review and manufacturing mean that everyday prescription use is unlikely before the late-2020s at the earliest.

      Why is type 2 diabetes not curable?

      Type 2 diabetes isn’t considered curable because its root problems—body-wide insulin resistance and gradual loss of insulin-producing β-cells—can return whenever weight or lifestyle slips, and adult β-cells don’t fully regrow once lost. Big, sustained weight loss (through diet, bariatric surgery, or powerful medications) can put the disease into remission for years, but the underlying susceptibility remains, which is why regular follow-up and healthy habits must continue even when blood sugar is normal.

      Can I stop taking metformin when my sugar is back to normal?

      Normal readings don’t necessarily mean diabetes is cured; for many people the numbers stay normal only because metformin is on board, and stopping it without a plan can let sugars creep back up. Talk with your clinician about whether you truly meet “remission” criteria (HbA1c < 6.5 % for at least 6 months, stable weight, good kidney function); if so, you can try a monitored dose-reduction, check home glucose and repeat labs in 3 months, and restart the drug promptly if levels rise. In short, never quit metformin on your own—make it a shared, step-by-step decision that includes a taper and clear follow-up.

      Can a person fully recover from diabetes?

      Type 1 diabetes cannot presently be cured; people need lifelong insulin. In type 2 diabetes, some individuals—especially soon after diagnosis—can achieve remission (normal blood-sugar readings without diabetes medicines) through substantial, sustained weight loss or bariatric surgery, but the underlying tendency can return, so regular check-ups remain essential. So while you may control or even “switch off” type 2 diabetes for a time, no form of diabetes is considered permanently gone.

      Which country has the cure for diabetes?

      No country has an approved, take-home “cure” for diabetes; the Chinese cell-therapy result you may have seen was a one-patient, early-stage experiment that still needs larger trials and regulatory review. Worldwide teams—from China to the United States, Canada, Europe and beyond—are testing stem-cell implants, gene editing and immune therapies, but for now the proven way to stay healthy is tight glucose monitoring, modern medications (e.g., metformin, GLP-1 or insulin) and lifestyle changes, with bariatric surgery offering remission for some people with type 2 diabetes. Stay alert for peer-reviewed trial results and discuss any experimental option with your diabetes specialist before pursuing treatment abroad.

      What is the record trial for diabetes?

      RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes) was a 5-year study of 4,458 adults with type 2 diabetes that compared adding rosiglitazone to metformin or a sulfonylurea versus the standard metformin-plus-sulfonylurea combination. It showed no overall difference in cardiovascular deaths or hospitalisations (hazard ratio 0.99), but rosiglitazone roughly doubled the risk of heart-failure events and increased bone fractures; these safety concerns, rather than glucose control, ultimately led regulators and doctors to curb use of the drug.

      What is the A1C goal for a 70 year old?

      For a 70-year-old who already has diabetes, guidelines use a sliding scale: aim below about 7–7.5 % if the person is otherwise healthy and independent, below 8 % if they have multiple illnesses or mild functional decline, and up to 8.5 % if they are frail or in long-term care—these higher limits reduce the risk of dangerous low-blood-sugar episodes. If the 70-year-old is only being screened, the usual cut-offs still apply (normal < 5.7 %, pre-diabetes 5.7-6.4 %, diabetes ≥ 6.5 % confirmed). Work with the healthcare team to choose the target that balances day-to-day safety with long-term benefit.

      Popular Searches

      By Condition

      Depression Clinical Trials in Texas

      Anxiety Clinical Trials in Texas

      Schizophrenia Clinical Trials in Texas

      ADHD Clinical Trials in Texas

      Bipolar Disorder Clinical Trials in Texas

      Multiple Sclerosis Clinical Trials in Texas

      Autism Clinical Trials in Texas

      Treatment Resistant Depression Clinical Trials in Texas

      Borderline Personality Disorder Clinical Trials in Texas

      Social Anxiety Disorder Clinical Trials in Texas

      Parkinson's Disease Clinical Trials in Texas

      Alzheimer's Disease Clinical Trials in Texas

      By Location

      Clinical Trials near Houston, TX

      Clinical Trials near Dallas, TX

      Clinical Trials near San Antonio, TX

      Clinical Trials near Austin, TX

      Clinical Trials near Fort Worth, TX

      Clinical Trials near Plano, TX

      Clinical Trials near Tyler, TX

      Clinical Trials near El Paso, TX

      Clinical Trials near Lubbock, TX

      Clinical Trials near Galveston, TX

      Clinical Trials near Temple, TX

      Clinical Trials near Arlington, TX

      Other People Viewed

      By Subject

      Top Clinical Trials near Houston, TX

      Top Weight Loss Clinical Trials near Houston, TX

      Top Lung Cancer Clinical Trials near Houston, TX

      Top Colorectal Cancer Clinical Trials near Houston, TX

      Top Breast Cancer Clinical Trials near Houston, TX

      Top Prostate Cancer Clinical Trials near Houston, TX

      55 Hypertension Trials near Houston, TX

      17 Autism Trials near Houston, TX

      Top Diabetes Clinical Trials near Plano, TX

      Top Diabetes Clinical Trials near Fort Worth, TX

      Top Depression Clinical Trials near Houston, TX

      Top Diabetes Clinical Trials

      By Trial

      Diabetes Self-Management Program for Type 2 Diabetes

      Continuous Glucose Monitoring for Type 1 Diabetes

      DPP + Doula Support for Gestational Diabetes

      Text Messaging for Diabetes Control in Homeless Populations

      Group Prenatal Care for Gestational Diabetes

      CGM Use for Diabetes

      Decision Support Tool for Prediabetes

      Genetic Risk Assessment for Type 2 Diabetes

      Behavioral Interventions for Type 2 Diabetes

      Meal Replacement Shake for Type 2 Diabetes

      Building Futures Program for Young People

      AT-001 for Diabetic Cardiomyopathy

      Related Searches

      Top Diabetes Clinical Trials near Las Vegas, NV

      Top Diabetes Clinical Trials near Los Angeles, CA

      Top Diabetes Clinical Trials near Miami, FL

      Top Diabetes Clinical Trials near Newport News, VA

      Top Diabetes Clinical Trials near New York, NY

      Top Diabetes Clinical Trials near Orlando, FL

      Top Diabetes Clinical Trials near Plano, TX

      Top Diabetes Clinical Trials near Provo, UT

      Top Diabetes Clinical Trials near Sacramento, CA

      Top Diabetes Clinical Trials near San Antonio, TX

      Top Diabetes Clinical Trials near San Diego, CA

      Top Diabetes Clinical Trials near San Jose, CA